Streptococcal β protein has separate binding sites for human factor H and IgA-Fc

被引:78
作者
Areschoug, T [1 ]
Stålhammar-Carlemalm, M [1 ]
Karlsson, I [1 ]
Lindahl, G [1 ]
机构
[1] Lund Univ, Dept Med Microbiol Dermatol & Infect, SE-22362 Lund, Sweden
关键词
D O I
10.1074/jbc.M112072200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The group B streptococcus (GBS) is the most important cause of life-threatening bacterial infections in newborn infants. Protective immunity to GBS infection is elicited by several surface proteins, one of which, the beta protein, is known to bind human IgA-Fc. Here, we show that the beta protein also binds human factor H (FH), a negative regulator of complement activation. Absorption experiments with whole human plasma demonstrated binding of FH to a GBS strain expressing beta protein but not to an isogenic beta-negative mutant. This binding was due to a direct interaction between beta and FH, as shown by experiments with purified proteins. Inhibition tests and studies with P fragments demonstrated that FH and IgA-Fc bind to separate and nonoverlapping regions in beta. Heparin, a known ligand for FH, specifically inhibited the binding between beta and FH, suggesting that FH has overlapping binding sites for beta and heparin. Bacteria-bound FH retained its complement regulatory activity, implying that beta-expressing GBS may use bound FH to evade complement attack. The finding that A protein binds FH adds to a growing list of interactions between human pathogens and complement regulatory proteins, supporting the notion that these interactions are of general importance in bacterial pathogenesis.
引用
收藏
页码:12642 / 12648
页数:7
相关论文
共 70 条
  • [1] Accardo P, 1996, J IMMUNOL, V157, P4935
  • [2] Areschoug T, 1999, INFECT IMMUN, V67, P6350
  • [3] Baker C.J., 1995, INFECT DIS FETUS NEW, V37, P980
  • [4] Berggard K, 1997, INFECT IMMUN, V65, P3638
  • [5] Binding of human C4BP to the hypervariable region of M protein:: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes
    Berggård, K
    Johnsson, E
    Morfeldt, E
    Persson, J
    Stålhammar-Carlemalm, M
    Lindahl, G
    [J]. MOLECULAR MICROBIOLOGY, 2001, 42 (02) : 539 - 551
  • [6] Berggärd K, 2001, EUR J IMMUNOL, V31, P2771, DOI 10.1002/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO
  • [7] 2-0
  • [8] BEVANGER L, 1985, ACTA PATH MICRO IM B, V93, P121
  • [9] BEVANGER L, 1979, ACTA PATH MICRO IM B, V87, P51
  • [10] Blackmore TK, 1996, J IMMUNOL, V157, P5422